AstraZeneca Pharma India First Quarter 2025 Earnings: ₹4.72 loss per share (vs ₹21.54 profit in 1Q 2024)
AstraZeneca Pharma India (NSE:ASTRAZEN) First Quarter 2025 Results
Key Financial Results
- Revenue: ₹3.96b (up 34% from 1Q 2024).
- Net loss: ₹117.9m (down by 122% from ₹538.6m profit in 1Q 2024).
- ₹4.72 loss per share (down from ₹21.54 profit in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
AstraZeneca Pharma India shares are down 4.8% from a week ago.
Risk Analysis
Be aware that AstraZeneca Pharma India is showing 3 warning signs in our investment analysis that you should know about...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:ASTRAZEN
AstraZeneca Pharma India
A biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally.
Flawless balance sheet low.
